BASF and Poietis sign an agreement to use 3D bioprinting technology. They intend to use bioprinting to research and develop innovative skin care products.
German company BASF SE and French company S.A.S Poietis, which labels itself as the first company in the world for 3D laser-assisted bioprinting, have concluded a research and development agreement in the area of cosmetics. Based on the combined expertise of the two companies, the agreement will apply Poietis’s bioprinting technology to further develop BASF’s skin equivalent model Mimeskin. The details on the terms and conditions of the agreement have not been released.
Poietis, located in Pessac in Southern France, was founded in 2014 as the winner of the French National Competition for Creation of Innovative Technology Companies and with the support of Aquitaine Regional Incubator. The 3D laser-assisted bioprinting technology, which can be used to reproduce organic tissue, makes it possible to arrange skin cells accurately in three-dimensional structures. It can be used to cultivate cells and introduce them in the BASF skin model Mimeskin, which is very similar to human skin.
According to Poietis founder and president, Dr. Fabien Guillemot, the partnership aims also to create bioprinted tissue models as an alternative to animal testing in cosmetics and dermopharmacy. The laser-assisted 3D bioprinting technology will first be used to reproduce Mimeskin automatically. Later these companies plan to develop models that contain other cell types.
Teilen:
